Amgenvs.Vertex Pharmaceuticals
AMGN vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 1.7× larger than Vertex Pharmaceuticals by market cap; Amgen trades at the lower P/E (25.8 vs 30.7); year to date, Amgen leads (+35.6% vs +20.8%).
Side by side
| AMGN | VRTX | |
|---|---|---|
| Market cap | $226B | $135B |
| Price | $442.24 | $552.85 |
| Today | −0.4% | +1.0% |
| Return YTD | +35.6% | +20.8% |
| Return 1Y | +51.1% | +38.6% |
| P/E | 25.8 | 30.7 |
| P/S | 5.9 | 10.7 |
| P/B | 19.3 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More AMGN & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.